RFM
CASI

Royal Fund Management’s CASI Pharmaceuticals CASI Stock Holding History

Royal Fund Management’s Portfolio CASI Stock Details CASI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Hold
0
– – – 629
2019
Q3 		– Hold
0
– – – 586
2019
Q2 		– Hold
0
– – – 551
2019
Q1 		– Hold
0
– – – 595
2018
Q4 		– Hold
0
– – – 588
2018
Q3 		– Sell
-1
Closed -$70 – 531
2018
Q2 		$0 Hold
1
– – ﹤0.01% 564
2018
Q1 		$0 Hold
1
– – ﹤0.01% 548
2017
Q4 		$0 Hold
1
– – ﹤0.01% 644
2017
Q3 		$0 Hold
1
– – ﹤0.01% 463
2017
Q2 		$0 Hold
1
– – ﹤0.01% 446
2017
Q1 		$0 Hold
1
– – ﹤0.01% 415
2016
Q4 		$0 Buy
+1
New +$14 ﹤0.01% 387

Other funds holding CASI

IACGFIA
IDG-Accel China Growth Fund III Associates Hong Kong $31.2M AUM 2.97% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WSCM
Wellington Shields Capital Management New York $788M AUM 66.95% 1-Year Est. Return
WSC
Wellington Shields & Co New York $446M AUM 38.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Royal Fund Management's CASI Position: Q4 2019 in Review

Royal Fund Management held its CASI Pharmaceuticals (CASI) position steady in Q4 2019 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #629.

Royal Fund Management first reported a position in CASI in Q4 2016 and has held it in 7 quarters since. The position peaked at $0 in Q2 2018. 53 funds tracked by Wall St. Rank hold CASI as of Q4 2019.

  • Royal Fund Management held 0 shares of CASI Pharmaceuticals worth $0 as of Q4 2019.
  • Royal Fund Management left its CASI Pharmaceuticals share count unchanged in Q4 2019.
  • CASI Pharmaceuticals made up ﹤0.01% of Royal Fund Management's portfolio in Q4 2019, its #629 holding.
  • Royal Fund Management first reported a position in CASI Pharmaceuticals in Q4 2016 and has held it in 7 quarters since.
  • Royal Fund Management's CASI Pharmaceuticals position peaked at $0 in Q2 2018.
  • 53 funds tracked by Wall St. Rank held CASI Pharmaceuticals as of Q4 2019.

Based on Royal Fund Management's 13F filing for Q4 2019, filed 11 May 2020.